Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL2215

CCCC[N+](CCCC)(CCCC)CCCC.O=[Mn](=O)(=O)[O-]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 4/20 0.67
SLC22A2 O15244 1/20 0.58
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
DNM1 Q05193 6/20 0.48
LSS P48449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL6694801 0.97 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL6694808 0.97 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL6694805 0.97 SLC22A1 (0.63) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3796267 0.97 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL20485063 0.84 SLC22A1 (0.52) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL27257891 0.83 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL1073228 0.83 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrapropylammonium SCHEMBL6686604 0.82 SLC22A1 (0.62) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL6949325 0.82 SLC22A1 (0.86) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL5724808 0.82 SLC22A1 (0.86) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178693-B Preparation method for catalyzing copolymerization of carbon dioxide and propylene oxide by using azoimidazole modified Mn-Mg nanocluster 安徽大学 2025-02-14 CN claimed
US-20240409431-A1 Metal Oxide having Spinel-Type Crystal Structure, Method for Producing Same, Carbon Dioxide Reduction Method, and Carbon Dioxide Reduction Apparatus TOHOKU UNIVERSITY (JP) 2024-12-12 US claimed
WO-2024177133-A1 MANGANESE DIOXIDE, POLYVALENT METAL ION SECONDARY BATTERY USING SAME, AND METHODS FOR MANUFACTURING SAME 国立大学法人北海道大学 2024-08-29 WO claimed
EP-4414330-A1 METAL OXIDE HAVING SPINEL-TYPE CRYSTAL STRUCTURE, METHOD FOR PRODUCING SAME, CARBON DIOXIDE REDUCTION METHOD, AND CARBON DIOXIDE REDUCTION APPARATUS Tohoku University (JP) 2024-08-14 EP claimed
CN-118019716-A Metal oxide having spinel-type crystal structure, method for producing same, method for reducing carbon dioxide, and carbon dioxide reduction device 国立大学法人东北大学 2024-05-10 CN claimed
CN-116178693-A Preparation method for catalyzing copolymerization of carbon dioxide and propylene oxide by using azoimidazole modified Mn-Mg nanocluster 安徽大学 2023-05-30 CN claimed
WO-2023058182-A1 METAL OXIDE HAVING SPINEL-TYPE CRYSTAL STRUCTURE, METHOD FOR PRODUCING SAME, CARBON DIOXIDE REDUCTION METHOD, AND CARBON DIOXIDE REDUCTION APPARATUS 国立大学法人東北大学 2023-04-13 WO claimed
CN-115850257-A Synthetic method of emodin amide derivatives containing coumarin thiazole and application of emodin amide derivatives in resisting marine vibrio 江苏海洋大学 2023-03-28 CN claimed
CN-112480031-B Emodin amide derivatives containing 1,3, 4-thiadiazole, and synthesis method and application thereof 江苏海洋大学 2022-05-20 CN claimed
CN-112480031-A Emodin amide derivatives containing 1,3, 4-thiadiazole, and synthesis method and application thereof 江苏海洋大学 2021-03-12 CN claimed
WO-2017044896-A1 BIOMEDICAL ADHESIVE AND SEALANT COMPOSITIONS AND METHODS OF USE DSM IP ASSETS B.V. (NL) 2017-03-16 WO claimed
CN-104761591-A Mn4CaO4 core structure-containing water cracking catalyst and preparation method and application thereof CHINESE ACAD INST CHEMISTRY 2015-07-08 CN claimed
US-8026200-B2 Low pH mixtures for the removal of high density implanted resist ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2011-09-27 US claimed
EP-2288965-A2 LOW PH MIXTURES FOR THE REMOVAL OF HIGH DENSITY IMPLANTED RESIST Advanced Technology Materials, Inc. (US) 2011-03-02 EP claimed
US-20090281016-A1 LOW pH MIXTURES FOR THE REMOVAL OF HIGH DENSITY IMPLANTED RESIST ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2009-11-12 US claimed
WO-2009135102-A2 LOW PH MIXTURES FOR THE REMOVAL OF HIGH DENSITY IMPLANTED RESIST ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2009-11-05 WO claimed
CN-101570486-A Method for preparing anomalous methyl ent-isocopalate UNIV EAST CHINA SCIENCE & TECH (CN) 2009-11-04 CN claimed
WO-2007118711-A1 17α-SUBSTITUTED 4-(3-OXOESTRA-4,9-DIEN-11β-YL)-BENZOIC ACID, ITS DERIVATIVES AND PROCESS FOR ITS PRODUCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-10-25 WO claimed
US-20070249573-A1 17alpha-substituted 4-(3-oxoestra-4,9-dien-11beta-yl)-benzoic acid, its derivatives and process for its production BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-10-25 US claimed
US-5288834-A Brominated chemical intermediate NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1994-02-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249573-A1 17alpha-substituted 4-(3-oxoestra-4,9-dien-11beta-yl)-benzoic acid, its derivatives and process for its production CYP19A1, HSD17B11, CYP2A13 SLC22A1 2422/4885SLC22A2 2629/4885ALDH1A1 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.